Literature DB >> 10770550

Association of HIV-1 load and CD4 lymphocyte count with mortality among untreated African children over one year of age.

T E Taha1, N I Kumwenda, D R Hoover, R J Biggar, R L Broadhead, S Cassol, L van der Hoven, D Markakis, G N Liomba, J D Chiphangwi, P G Miotti.   

Abstract

OBJECTIVE: To examine the association of viral load and CD4 lymphocyte count with mortality among HIV-infected children over one year of age.
DESIGN: A prospective study. HIV-infected children were enrolled during the first year of life and followed for more than 2 years at the Queen Elizabeth Central Hospital in Blantyre, Malawi (southeast Africa).
METHODS: Morbidity and mortality information was collected every 3 months, and physical examination and blood testing (for viral level and CD4 cell percentage) were performed every 6 months. Kaplan-Meier analyses and proportional hazards models were used to estimate survival and to examine the association of primary predictors with mortality.
RESULTS: Of 155 HIV-infected children originally enrolled, 115 (74%) had viral load testing and 82 (53%) had both viral load and CD4 cell percentage testing after their first year. Among children over one year of age, significant associations were found between mortality and the log10 viral load and CD4 cell percentage in both univariate and multivariate models. Independent of the CD4 cell value, a one unit log10 increase in HIV RNA level increased the hazard of child mortality by more than twofold. Children with low CD4 cell counts (< 15%) and high viral loads (> or = 250,000 copies/ml median value) had the worst survival; children with high CD4 cell counts (> or = 15%) and low viral loads (< 250,000 copies/ml) had the best survival.
CONCLUSION: As in developed countries, viral load and CD4 cell count are the main predictors of mortality among African children. Making these tests available adds to the challenges to be considered if antiviral therapies were to be adopted in these countries.

Entities:  

Mesh:

Year:  2000        PMID: 10770550     DOI: 10.1097/00002030-200003100-00021

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  10 in total

1.  Viral load, CD4+ T-lymphocyte counts and antibody titres in HIV-1 infected untreated children in Kenya; implication for immunodeficiency and AIDS progression.

Authors:  Washingtone Ochieng; Dorington Ogoyi; Francis J Mulaa; Simon Ogola; Rachel Musoke; Moses G Otsyula
Journal:  Afr Health Sci       Date:  2006-03       Impact factor: 0.927

2.  Short-term risk of HIV disease progression and death in Ugandan children not eligible for antiretroviral therapy.

Authors:  Edwin D Charlebois; Theodore D Ruel; Anne F Gasasira; Jane Achan; Frederick Kateera; Caroline Akello; Huyen Cao; Grant Dorsey; Philip J Rosenthal; Isaac Ssewanyana; Moses R Kamya; Diane V Havlir
Journal:  J Acquir Immune Defic Syndr       Date:  2010-11       Impact factor: 3.731

3.  Population attributable fractions for late postnatal mother-to-child transmission of HIV-1 in Sub-Saharan Africa.

Authors:  Ying Q Chen; Alicia Young; Elizabeth R Brown; Charles S Chasela; Susan A Fiscus; Irving F Hoffman; Megan Valentine; Lynda Emel; Taha E Taha; Robert L Goldenberg; Jennifer S Read
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

4.  Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected african children.

Authors:  Elizabeth M Obimbo; Dorothy A Mbori-Ngacha; James O Ochieng; Barbra A Richardson; Phelgona A Otieno; Rose Bosire; Carey Farquhar; Julie Overbaugh; Grace C John-Stewart
Journal:  Pediatr Infect Dis J       Date:  2004-06       Impact factor: 2.129

5.  Total lymphocyte count: not a surrogate marker for risk of death in HIV-infected Ugandan children.

Authors:  Philippa M Musoke; Alicia M Young; Maxensia A Owor; Irene R Lubega; Elizabeth R Brown; Francis A Mmiro; Lynne M Mofenson; J Brooks Jackson; Mary Glenn Fowler; Laura A Guay
Journal:  J Acquir Immune Defic Syndr       Date:  2008-10-01       Impact factor: 3.731

6.  Survival from 9 months of age among HIV-infected and uninfected Zambian children prior to the availability of antiretroviral therapy.

Authors:  Catherine G Sutcliffe; Susana Scott; Nanthalile Mugala; Zaza Ndhlovu; Mwaka Monze; Thomas C Quinn; Simon Cousens; Diane E Griffin; William J Moss
Journal:  Clin Infect Dis       Date:  2008-09-15       Impact factor: 9.079

7.  Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection.

Authors:  Barbra A Richardson; Dorothy Mbori-Ngacha; Ludo Lavreys; Grace C John-Stewart; Ruth Nduati; Dana D Panteleeff; Sandra Emery; Joan K Kreiss; Julie Overbaugh
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

8.  Total lymphocyte count and World Health Organization pediatric clinical stage as markers to assess need to initiate antiretroviral therapy among human immunodeficiency virus-infected children in Moshi, Northern Tanzania.

Authors:  Opemipo O Johnson; Daniel K Benjamin; Daniel K Benjamin; Werner Schimana; L Gayani Tillekeratne; John A Crump; Keren Z Landman; Grace D Kinabo; Blandina Mmbaga; Levina J Msuya; John F Shao; Mark E Swai; Coleen K Cunningham
Journal:  Pediatr Infect Dis J       Date:  2009-06       Impact factor: 2.129

9.  Incidence of World Health Organization stage 3 and 4 events, tuberculosis and mortality in untreated, HIV-infected children enrolling in care before 1 year of age: an IeDEA (International Epidemiologic Databases To Evaluate AIDS) East Africa regional analysis.

Authors:  Andrea Ciaranello; Zhigang Lu; Samuel Ayaya; Elena Losina; Beverly Musick; Rachel Vreeman; Kenneth A Freedberg; Elaine J Abrams; Lisa Dillabaugh; Katie Doherty; John Ssali; Constantin T Yiannoutsos; Kara Wools-Kaloustian
Journal:  Pediatr Infect Dis J       Date:  2014-06       Impact factor: 2.129

10.  Commentary: Questioning the HIV-AIDS Hypothesis: 30 Years of Dissent.

Authors:  Alexey Karetnikov
Journal:  Front Public Health       Date:  2015-08-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.